PMID- 34066684
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20230920
IS  - 1648-9144 (Electronic)
IS  - 1010-660X (Print)
IS  - 1010-660X (Linking)
VI  - 57
IP  - 5
DP  - 2021 May 8
TI  - Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
LID - 10.3390/medicina57050458 [doi]
LID - 458
AB  - Despite advanced diseases continuing to be associated with grim prognoses, the 
      past decade has witnessed the advent of several novel treatment options for 
      cholangiocarcinoma (CCA) patients. In fact, CCA has emerged as a heterogeneous 
      group of malignancies harboring potentially druggable mutations in approximately 
      50% of cases, and thus, molecularly targeted therapies have been actively 
      explored in this setting. Among these, fibroblast growth factor receptor (FGFR) 
      inhibitors have reported important results, as witnessed by the FDA approval of 
      pemigatinib in previously treated metastatic CCA patients harboring FGFR2 fusion 
      or other rearrangements. Herein, we provide an overview of available evidence on 
      FGFR inhibitors in CCA, especially focusing on the development, pitfalls and 
      challenges of emerging treatments in this setting.
FAU - Rizzo, Alessandro
AU  - Rizzo A
AUID- ORCID: 0000-0002-5257-8678
AD  - Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi 
      University Hospital, 40138 Bologna, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210508
PL  - Switzerland
TA  - Medicina (Kaunas)
JT  - Medicina (Kaunas, Lithuania)
JID - 9425208
RN  - 0 (Morpholines)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2)
RN  - Y6BX7BL23K (pemigatinib)
SB  - IM
MH  - *Bile Duct Neoplasms/drug therapy/genetics
MH  - Bile Ducts, Intrahepatic
MH  - *Cholangiocarcinoma/drug therapy/genetics
MH  - Humans
MH  - Morpholines
MH  - Pyrimidines
MH  - Pyrroles
MH  - Receptor, Fibroblast Growth Factor, Type 2/genetics
PMC - PMC8151905
OTO - NOTNLM
OT  - FGFR
OT  - cholangiocarcinoma
OT  - intrahepatic cholangiocarcinoma
OT  - pemigatinib
OT  - targeted therapies
COIS- The author declares no conflict of interest.
EDAT- 2021/06/03 06:00
MHDA- 2021/06/04 06:00
PMCR- 2021/05/08
CRDT- 2021/06/02 01:17
PHST- 2021/03/27 00:00 [received]
PHST- 2021/04/26 00:00 [revised]
PHST- 2021/05/04 00:00 [accepted]
PHST- 2021/06/02 01:17 [entrez]
PHST- 2021/06/03 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2021/05/08 00:00 [pmc-release]
AID - medicina57050458 [pii]
AID - medicina-57-00458 [pii]
AID - 10.3390/medicina57050458 [doi]
PST - epublish
SO  - Medicina (Kaunas). 2021 May 8;57(5):458. doi: 10.3390/medicina57050458.